Day One Biopharmaceuticals Accepts $2.5B Acquisition

Day One Biopharmaceuticals Inc. (NASDAQ:DAWN) said this week that France-based Servier will acquire the company for $2.5 billion, tendering all shares at $21.50 apiece. The offer represents a 68% premium to the $12.78 pre-announcement close and is expected to close in the second quarter, subject to customary closing conditions and shareholder approval.